A Randomized, Active-controlled, Patient and Investigator-masked, Multiple Dose Proof-of-concept Study of Intravitreal LKA651 in Patients With Diabetic Macular Edema

  • STATUS
    Recruiting
  • participants needed
    90
  • sponsor
    Novartis Pharmaceuticals
Updated on 27 September 2022
diabetes
type 2 diabetes mellitus
lucentis
spectral domain optical coherence tomography

Summary

To evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),

Details
Condition Diabetic Macular Edema
Treatment Lucentis, LKA651
Clinical Study IdentifierNCT03927690
SponsorNovartis Pharmaceuticals
Last Modified on27 September 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note